Business Wire

NY-MOODY'S-ANALYTICS

Share
Moody’s Analytics to Provide Certification for Hungarian Mortgage Professionals

Moody's Analytics has announced the launch of the Certification of Professional Competence in Mortgage Lending in Hungary, in collaboration with the Budapest Institute of Banking (BIB) and the International Training Center for Bankers (ITCB).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005060/en/

The certification program meets the requirements of the European Parliament and Council Directive on Mortgage Credit. The objective of the mandate is to ensure a minimum standard of competency and ethics among mortgage lenders, specifically applicable to the following roles:
- Bank professionals in the front, middle and back office engaged in residential mortgage lending (for example, product design, underwriting, administration and management, as well as selling)
- Mortgage brokers who propose, offer, and/or sell residential mortgages
- Managers of employees listed above
- Individuals aspiring to work in any position related to the Hungarian mortgage market

Beyond meeting regulatory requirements, the program is designed to elevate the consultative skills of lending professionals and help them become responsible advisers to their customers, in line with the objectives of Hungarian banks and the evolving expectations of the market.

The program delivers a modern learning experience by using advanced technology to personalize the learning and expedite the impact while minimizing the workload for those who already possess the required skills.

Gergely Fábián, Chief Executive Officer of BIB, noted, “We are delighted to work with Moody’s Analytics and to bring their educational framework and professional knowledge in mortgage lending to Hungary. The program aims to instill best practices in lending for mortgage lenders in the Hungarian Banking industry.”

Béla Öcsi, Chief Executive Officer of the ITCB, added, “The innovative Credit Coach framework from Moody’s Analytics brings an enhanced learning experience for all participants. We are pleased to be able to deliver substantial value to the local banking sector through the collaboration with BIB and Moody’s Analytics.”

“We are honored to collaborate with the BIB and ITCB to deliver a program that represents the highest standards in international credit practices, adapted to the unique context of the Hungarian banking industry,” added Ari Lehavi, Executive Director at Moody’s Analytics. “We look forward to supporting similar institutes across the region in their goal of addressing the certification requirements of the European Mortgage Credit Directive, as applicable in their local market.”

Moody’s Analytics recently collaborated with the Hellenic Banking Institute to offer the Certification of Professional Competence in Mortgage Lending program in Greece.

Click here to learn more about Moody’s Analytics Learning Solutions, including Credit Coach.

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .

Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.

About the Budapest Institute of Banking

The foundation of the Budapest Institute of Banking (BIB) is rooted in the matching of market needs with the social responsibility objectives of the Magyar Nemzeti Bank (the Central Bank of Hungary) and the Budapest Stock Exchange.

A modern education centre has been created where up-to-date knowledge is transferred in the form of experience-based learning. Forms of edutainment are an integral part of the teaching methodology. Covering the entire operational range of the banking, financial, and insurance sector, the courses grant the opportunity to participants, from experts to top managers, to gain cutting-edge knowledge and to discover professional development opportunities.

The BIB aims to train experts who will be able to address the challenges of the future.

For more information please visit our website: https://www.bib-edu.hu/en .

About International Training Center for Bankers (ITCB)

Founded 30 years ago, ITCB has been providing quality financial education and specialized risk consultancy services for the banking sector in Hungary, Central and Eastern Europe and the Middle East. Building on its long track record and synergies between advisory and training, ITCB’s current offering focuses on tailor-made case study-driven banking seminars, e-learning courses and financial simulations. For more information about ITCB, visit our website .

Contact:

KATERINA SOUMILOVA Moody’s Analytics Communications +1.212.553.1177

Moody's Analytics Media Relations

moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye